Aktuellt
SENASTE
Redeye provides a research note on Faron Pharmaceuticals following the announcement of a convertible bond agreement of up to EUR35m. Overall, we are encouraged to see that the company has proactively found a solution to repay its secured loan to IPF and strengthen its financial position. While entailing potential dilution concerns, we believe that this strengthens the company’s position in business development and licensing negotiations, placing the company in a position where it can increase shareholder value.
